Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
Open Access
- 20 September 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 13 (1), 427
- https://doi.org/10.1186/1471-2407-13-427
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel)Alimentary Pharmacology & Therapeutics, 2011
- Advances in Pancreatic Neuroendocrine Tumor TreatmentThe New England Journal of Medicine, 2011
- Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumoursAlimentary Pharmacology & Therapeutics, 2009
- Gastrointestinal neuroendocrine tumors: a role for targeted therapies?Endocrine-Related Cancer, 2007
- Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumorsCancer, 2006
- Rationale for the use of somatostatin analogs as antitumor agentsAnnals of Oncology, 2006
- Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study GroupJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Ultra-High-Dose Lanreotide Treatment in Patients with Metastatic Neuroendocrine Gastroenteropancreatic TumorsDigestion, 1999
- Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.Gut, 1996